iShares Global Tech ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Global Tech ETF trades at $142.15, while State Street SPDR S&P Biotech ETF trades at $159.35. Which is the better fit depends on your goals.
| IXN | XBI | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $149.74 | $164.28 |
52-Week Low | $94.42 | $86.92 |
Signals from Pluang's Aura AI — not financial advice
IXN trades at $142.54, up 2.24% with strong technical momentum as moving averages signal bullish sentiment. The ETF shows robust technical positioning near resistance levels while maintaining neutral oscillator readings. Recent dividend activity and global tech exposure highlight its investment profile.
Outlook remains cautiously optimistic given high valuations and concentration risks in tech holdings. Key opportunities include AI-driven growth exposure, while risks involve stretched valuations and sector volatility. Analyst consensus suggests holding for strategic tech allocation.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Trailing returns across standard periods
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →